Skip to main content
OpenTrials
Completed

NCT Number: NCT05037305

VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey

The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine. However, there are limited data supporting drug-gene associations for children and for women during and after pregnancy. The unique physiology of childhood and pregnancy demand validation of pharmacogenetic signals prior to clinical implementation. These knowledge gaps are compounded for individuals from minority populations, who have been underrepresented and thus underserved by genomic research and specifically pharmacogenetic studies. The primary objective of this project is to advance research and support clinical implementation in pharmacogenetics for children and pregnant women. This work will illuminate knowledge of, attitudes about, and priorities for pharmacogenetics, and will assess the impact of a brief educational video on knowledge and attitudes around pharmacogenetic testing. The investigators will assess the knowledge and attitudes regarding pharmacogenetic testing among diverse cohorts of children with chronic conditions and pregnant women, before and after receiving pharmacogenetic test results. Participants will be randomized to view an educational video about pharmacogenetic testing either at the time of receiving their pharmacogenetic test results, or at a later time. The investigators will perform surveys before and after pharmacogenomic testing and return of results, and before and after watching the educational video.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pharmacogenomic Testing

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States

Loading trial locations.

About this study

This study will follow a two-arm unblinded research design. Study inclusion criteria include ability to provide a DNA sample for pharmacogenetic (PGx) testing and willingness to receive the test results. All participants will have PGx testing. Participants will complete a survey at study baseline, which will collect demographic information (age, race/ethnicity), contact and alternative contact information, primary care physician information, socioeconomic details (e.g. insurance information, education, occupation, marital status, and income) health data (e.g. chronic conditions, personal and family history of genetic diseases) and lifestyle data (e.g. smoking, drinking, and physical activity). Parents will complete enrollment surveys on behalf of children. Basic health and pregnancy history will also be collected for pregnant women. Survey questions regarding information and knowledge on PGx testing will be administered at enrollment and again after return of PGx results. Participants will be randomized to either the intervention group or the delayed intervention group. Individuals in the intervention group will be provided an educational video about PGx testing at the time that PGx results are available. Participants in the Delayed intervention group will be provided the educational video after they complete the first follow up survey. The investigators will include questions in the follow-up survey specific to the educational video in the first follow up survey (Intervention group) or the second follow up survey (Delayed intervention group).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Maternal

Inclusion criteria

  • Provide consent in English or Spanish
  • Primary care at VUMC
  • Adult women aged 18 and older
  • Currently pregnant 12 to 30 weeks gestational age
  • Completed or scheduled first prenatal visit at VUMC clinic
  • Intent to deliver at VUMC or affiliate
  • Agrees to receive findings from pharmacogenomic testing
  • Allow access their medical record

Exclusion criteria

  • Stem cell or solid organ transplant
  • Recent transfusion within the previous 2 months
  • Inability to provide DNA sample for testing
  • Prior pharmacogenomic testing
  • Pregnant women undergoing in vitro fertilization or assisted reproductive technologies

Pediatric

Inclusion criteria

  • Provide consent (parent/guardian) and/or assent (child) in English or Spanish
  • Primary care or subspecialty care at VUMC
  • Aged 0 to 16
  • Parent (0-16 years) and child (12-16 years) agree for both parent and child to receive findings from pharmacogenomic testing
  • Parent (0-16 years) and child (12-16 years) allow access their medical record
  • Have a chronic health condition.

Exclusion:

  • Stem cell or solid organ transplant
  • Recent transfusion within the previous 2 months
  • Inability to provide DNA sample for testing
  • Prior pharmacogenomic testing

Treatment and study plan

Educational Video

Other

The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.

Primary outcomes

  1. Participants' opinions of pharmacogenetic testing changes after results are received

    Time frame: Baseline to post-return of PGx results, approximately 2- 4 weeks

    • Opinion of Knowledge of Pharmacogenetics (PGx) and Related Terminology is being collected in 3 ways. Ten words or phrases will be assessed using a 5-variable ordinal scale ('Not at all familiar' to 'Extremely familiar'). One question will use a 4-variable ordinal scale (Very well, somewhat well, a little, not at all). Another question will use a 5-option Likert scale (A lot, somewhat, a little, not at all, don't know).
    • Opinion of the Usefulness of PGx Testing is being collected using 12 statements with 5-variable ordinal scales ('Strongly disagree' to 'Strongly agree').
    • Opinion of What Can be Learned from PGx Test Results is being collected using 9 statements with 5-variable ordinal scales ('Strongly disagree' to 'Strongly agree').

    For all 3 above, responses reflect relative value, not absolute value, so are not additive and there are no total scores.

Secondary outcomes

  1. Participants gain an improved knowledge of pharmacogenetics after educational intervention

    Time frame: Baseline to post-return of PGx results, approximately 2-4 weeks

    • The 3 sections for Outcome 1 will also be asked to individuals who receive the educational video after they've received their PGx test results (as opposed to those who receive the results and video at the same time). These questions will be used in a pre-post analysis to investigate potential changes in knowledge after receiving the educational intervention.
    • Opinion of the Educational Video: Participants will also be asked questions regarding the video to gauge their perceptions of the utility. These questions are being collected using a 5-variable ordinal scale. There are 4 statements in this section. Response options range from 'Strongly disagree' to 'Strongly agree'. Level of agreement with and understanding of terms is being measured, and responses reflect relative value, not absolute value, so are not additive and there is no total score.

  2. Researchers gain a better understanding of the concerns about and perceptions of pharmacogenetic testing among pregnant women and parents of children with chronic conditions

    Time frame: Baseline to post-return of PGx results, approximately 2- 4 weeks

    • Preferences and Comfort on Their Healthcare Providers Accessing and Using Their PGx Test is assessed using 6 questions with 5-point Likert scales ('Strongly disagree' to 'Strongly agree').
    • Attitudes Regarding PGx Testing and Benefits of the Study are being collected through a matrix block of 12 statements with 5-point Likert scales ('Strongly disagree' to 'Strongly agree').
    • Factors Relating to Decision to Get PGx Testing is measured through a matrix of 8 questions with 5-point Likert scales ('Strongly disagree' to 'Strongly agree').
    • Preference on Provider Who Orders, and Explains PGx Tests will be gauged using 2 "select all that apply" questions.
    • Understanding of, Trust in, and Confidence in Prescriptions after PGx Test Results will be measured with 1 question each.

    For all above, responses reflect relative value, not absolute value, so are not additive and there are no total scores.

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Official study title

Knowledge and Attitudes Regarding Pharmacogenetic Testing Among Children With Chronic Conditions and Pregnant Women

Acronym: MPRINT

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Sep 8, 2021
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.